Fixed-Course Antibiotics Good for Intraabdominal Infection

This article originally appeared here.
Share this content:
Fixed-Course Antibiotics Good for Intraabdominal Infection
Fixed-Course Antibiotics Good for Intraabdominal Infection

(HealthDay News) -- For patients with complicated intraabdominal infection, outcomes are similar for fixed-duration antibiotic therapy and antibiotic therapy that is extended until symptom resolution, according to a study published in the May 21 issue of the New England Journal of Medicine.

Robert G. Sawyer, M.D., from the University of Virginia Health System in Charlottesville, and colleagues randomized 518 patients with complicated intraabdominal infection and adequate source control to receive antibiotics until two days after the resolution of fever, leukocytosis, and ileus (control) or a fixed course of antibiotics (experimental group) for four days.

The researchers found that 21.8 percent of the experimental group and 22.3 percent of the control group had surgical-site infection, recurrent intraabdominal infection, or death (P = 0.92). The median duration of antibiotic therapy was 4.0 and 8.0 days in the experimental and control groups, respectively (P < 0.001). There were no significant differences between the groups with respect to the individual rates of the components of the primary outcome or other secondary outcomes.

"Outcomes in patients with intraabdominal infections who have undergone a successful source-control procedure and receive a fixed, four-day course of antimicrobial therapy appear to be generally similar to outcomes in patients in whom systemic antimicrobial agents are administered until after the resolution of signs and symptoms of sepsis," the authors write.

Several authors disclosed financial ties to pharmaceutical companies.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »